Perspective Therapeutics, Inc. 8-K

What Happened
Perspective Therapeutics, Inc. (CATX) filed a Form 8-K on May 4, 2026 (Items 2.02 and 8.01) to post a presentation from an analyst event held that day. The Presentation includes slides on the company’s clinical programs, manufacturing infrastructure and preliminary estimated financial information — specifically an estimated balance of cash, cash equivalents and short-term investments as of March 31, 2026. The company notes this financial information is preliminary, unaudited and that WithumSmith+Brown, PC (the company’s independent registered public accounting firm) has not completed procedures or expressed any assurance on those figures. The filing is signed by Joel Sendek, Chief Financial Officer, and the Presentation is filed as Exhibit 99.1.

Key Details

• Date filed: May 4, 2026; items reported: 2.02 (Results of Operations and Financial Condition) and 8.01 (Other Events).
• Presentation includes preliminary estimated cash, cash equivalents and short-term investments as of March 31, 2026 (amounts presented are unaudited/preliminary).
• Independent auditor Withum has not completed procedures and expresses no opinion on the preliminary figures.
• Presentation covers clinical programs and manufacturing slides and is filed as Exhibit 99.1 to the 8-K.

Why It Matters
For investors, this 8-K provides an early look at Perspective’s operational slides and a preliminary snapshot of liquidity as of March 31, 2026. However, the cash figures are unaudited and subject to change pending closing procedures, final adjustments and the company’s formal quarterly filings (e.g., 10-Q). Treat the numbers as provisional — useful for context but not a substitute for finalized quarterly results or audited statements.